Pasireotide (SOM230) is Effective for the Treatment of Pancreatic Neuroendocrine Tumors (PNETs) in a Multiple Endocrine Neoplasia Type 1 (MEN1) Conditional Knockout Mouse Model

BACKGROUND: Pasireotide (SOM230), a long acting somatostatin analogue (LAR) has improved agonist activity at somatostatin receptors. We tested the effect of SOM230 on insulin secretion, glucose levels, tumor growth, and survival using an MEN1 transgenic mouse model. METHODS: Eight 12 month-old condi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Quinn, Thomas J., Yuan, Ziqiang, Adem, Asha, Geha, Rula, Vrikshajanani, Chakravarthy, Koba, Wade, Fine, Eugene, Hughes, David T., Schmid, Herbert, Libutti, Steven K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3732168/
https://ncbi.nlm.nih.gov/pubmed/23102680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.surg.2012.08.021
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak